ponatinib,blinatumomab
otsuka,incyte,astellas pharmaceuticals,amgen,takeda
['cml', 'leusm', 'blinatumomab', 'ponatinib', 'leukemia']
congress #eha2022 | reports on a phase ii study of ponatinib + blinatumomab in pts with either nd ph+all, r/r ph+all or cml. n=55, cr/cri: nd all pts=96%, r/r ph+all pts=92%, cml pts=83% #allsm #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm